Literature DB >> 24534279

Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria.

Wael A Salameh1, Mildred M Redor-Goldman1, Nigel J Clarke1, Ruchi Mathur2, Ricardo Azziz3, Richard E Reitz1.   

Abstract

OBJECTIVE: To determine whether liquid chromatography-tandem mass spectrometry (LC-MS/MS) determination of total (TT) and free (FT) testosterone is more specific than extraction chromatography-radioimmunoassay (RIA) for distinguishing women with polycystic ovary syndrome (PCOS) from controls and whether differing cutoff values should be used depending on the setting.
DESIGN: Prospective case-control cohort study.
SETTING: Tertiary care center and reference laboratory. INTERVENTION(S): Blood sampling. PATIENT(S): One hundred patients with PCOS and 100 controls. MAIN OUTCOME MEASURE(S): Circulating TT measured by RIA and LC-MS/MS and FT measured by equilibrium dialysis using RIA or LC-MS/MS-generated TT values. RESULT(S): T measurement by RIA and LC-MS/MS similarly differentiated patients with PCOS from controls; detection of PCOS was higher for FT for both methods. TT values demonstrated greater overlap between patients with PCOS and controls than did FT for both RIA (80% vs. 42% overlap) and LC-MS/MS (52% vs. 67% overlap). A lower cutoff value by LC-MS/MS was better suited for the study of patients seen in the clinical (referred) setting (35 and 4.0 ng/dL for TT and FT, respectively) than in the screening of a general population (50 and 5.0 ng/dL for TT and FT, respectively). CONCLUSION(S): Extraction chromatography-RIA and LC-MS/MS measurements of T have similar performance for differentiating patients with PCOS from healthy controls; LC-MS/MS may be preferable given its relative ease of automation. Compared with FT, measurement of TT has relatively limited value for distinguishing PCOS from normal. Finally, different cutoff values should be considered depending on the clinical/investigative setting, with higher values being used in the study of biased (e.g., clinical or referred) populations.
Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Polycystic ovary syndrome; androgens; mass spectrometry; radioimmunoassays; testosterone

Mesh:

Substances:

Year:  2014        PMID: 24534279      PMCID: PMC4123453          DOI: 10.1016/j.fertnstert.2013.12.056

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  24 in total

Review 1.  Measurement of androgens in women.

Authors:  Frank Z Stanczyk
Journal:  Semin Reprod Med       Date:  2006-04       Impact factor: 1.303

2.  Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry.

Authors:  Christina Wang; Don H Catlin; Laurence M Demers; Borislav Starcevic; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

3.  Testosterone measurement by isotope-dilution liquid chromatography-tandem mass spectrometry: validation of a method for routine clinical practice.

Authors:  Marion L Cawood; Helen P Field; Clive G Ford; Scott Gillingwater; Andrew Kicman; David Cowan; Julian H Barth
Journal:  Clin Chem       Date:  2005-06-16       Impact factor: 8.327

4.  Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups.

Authors:  Wendy Y Chang; Eric S Knochenhauer; Alfred A Bartolucci; Ricardo Azziz
Journal:  Fertil Steril       Date:  2005-06       Impact factor: 7.329

Review 5.  Measurement of androgens.

Authors:  Michael J Wheeler
Journal:  Methods Mol Biol       Date:  2006

6.  Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.

Authors:  E Carmina; F Rosato; A Jannì; M Rizzo; R A Longo
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

7.  Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.

Authors:  William Rosner; Richard J Auchus; Ricardo Azziz; Patrick M Sluss; Hershel Raff
Journal:  J Clin Endocrinol Metab       Date:  2006-11-07       Impact factor: 5.958

8.  The prevalence and features of the polycystic ovary syndrome in an unselected population.

Authors:  Ricardo Azziz; Keslie S Woods; Rosario Reyna; Timothy J Key; Eric S Knochenhauer; Bulent O Yildiz
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

9.  Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.

Authors:  E S Knochenhauer; T J Key; M Kahsar-Miller; W Waggoner; L R Boots; R Azziz
Journal:  J Clin Endocrinol Metab       Date:  1998-09       Impact factor: 5.958

Review 10.  The adrenal and polycystic ovary syndrome.

Authors:  Bulent O Yildiz; Ricardo Azziz
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

View more
  11 in total

1.  Alterations in plasma non-esterified fatty acid (NEFA) kinetics and relationship with insulin resistance in polycystic ovary syndrome.

Authors:  Uche Ezeh; Zorayr Arzumanyan; Daria Lizneva; Ruchi Mathur; Yen-Hao Chen; Raymond C Boston; Y-D Ida Chen; Ricardo Azziz
Journal:  Hum Reprod       Date:  2019-02-01       Impact factor: 6.918

2.  Adipocyte Insulin Resistance in PCOS: Relationship With GLUT-4 Expression and Whole-Body Glucose Disposal and β-Cell Function.

Authors:  Uche Ezeh; Ida Y-D Chen; Yen-Hao Chen; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2020-07-01       Impact factor: 5.958

3.  Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS).

Authors:  Eleftherios P Diamandis; Frank Z Stanczyk; Sarah Wheeler; Anu Mathew; Martin Stengelin; Galina Nikolenko; Eli N Glezer; Marshall D Brown; Yingye Zheng; Yen-Hao Chen; Hsiao-Li Wu; Ricardo Azziz
Journal:  Clin Chem Lab Med       Date:  2017-10-26       Impact factor: 3.694

4.  Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys.

Authors:  D H Abbott; B H Rayome; D A Dumesic; K C Lewis; A K Edwards; K Wallen; M E Wilson; S E Appt; J E Levine
Journal:  Hum Reprod       Date:  2017-04-01       Impact factor: 6.918

5.  Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements.

Authors:  Yabo Yang; Miao Ding; Na Di; Ricardo Azziz; Dongzi Yang; Xiaomiao Zhao
Journal:  J Clin Lab Anal       Date:  2018-10-23       Impact factor: 2.352

Review 6.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

7.  Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.

Authors:  U Ezeh; M D Pisarska; R Azziz
Journal:  Hum Reprod       Date:  2022-03-01       Impact factor: 6.918

8.  Screening for Androgen Excess in Women: Accuracy of Self-Reported Excess Body Hair Growth and Menstrual Dysfunction.

Authors:  Jessica L Chan; Marita Pall; Uche Ezeh; Ruchi Mathur; Margareta D Pisarska; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

Review 9.  Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology.

Authors:  Roshan Dadachanji; Nuzhat Shaikh; Srabani Mukherjee
Journal:  Genet Res Int       Date:  2018-02-18

10.  Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations.

Authors:  M Geoffrey Hayes; Margrit Urbanek; David A Ehrmann; Loren L Armstrong; Ji Young Lee; Ryan Sisk; Tugce Karaderi; Thomas M Barber; Mark I McCarthy; Stephen Franks; Cecilia M Lindgren; Corrine K Welt; Evanthia Diamanti-Kandarakis; Dimitrios Panidis; Mark O Goodarzi; Ricardo Azziz; Yi Zhang; Roland G James; Michael Olivier; Ahmed H Kissebah; Elisabet Stener-Victorin; Richard S Legro; Andrea Dunaif
Journal:  Nat Commun       Date:  2015-08-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.